Health and Healthcare

Health and Healthcare Articles

Illumina shares dropped on Friday after the firm announced a preliminary revenue miss and a 50% cut to its 2019 revenue growth guidance. As a result, a few analysts were quick to weigh in on the...
Leading health care data and analytics technology and services provider Health Catalyst aims to price 6 million shares for an initial public offering is valued up to more than $158 million.
Hookipa Pharma is not a household name, or even well-known within the biotech industry, but it is making waves on Friday after the firm announced an update from the FDA.
24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies. The June 28 short interest data has been compared with the previous report, and short interest in most...
The June 28 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were increased.
President Trump lost ground with his efforts to force drug companies to list drug prices on TV ads, with the effort being blocked on free speech concerns.
Microsoft announced that it is working with Providence St. Joseph Health, a U.S. hospital chain, in an effort to build a new high-tech hospital.
A federal District Court judge on Tuesday ruled that the U.S. Department of Health and Human Services could not force drug companies to include drug prices in their TV ads. But the saga may not be...
Sangamo Therapeutics made a handy gain to start out the week after the firm, in conjunction with Pfizer, announced updated results from a mid-stage trial evaluating a treatment for hemophilia.
Intra-Cellular Therapies has announced top-line results from its two late-stage trial in patients with bipolar depression.
24/7 Wall St. has picked a few of those standouts from Tuesday to highlight. We have included information about each company, as well as recent trading activity and the consensus analyst price target.
Pfizer shares were up slightly on Monday after the firm announced topline results from its most recent late-stage study in young children with mild to moderate atopic dermatitis, also known as eczema.
Pfizer released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy. While these results did not necessarily live up to expectations, there is a winner in this.
AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.